Dynavax Historical Income Statement

DVAX Stock

USD 12.36 0.19 1.56%

Historical analysis of Dynavax Technologies income statement accounts such as Other Operating Expenses of 282.8 M or Ebit of 2.5 M can show how well Dynavax Technologies performed in making a profits. Evaluating Dynavax Technologies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Dynavax Technologies's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Dynavax Technologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dynavax Technologies is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.

About Dynavax Income Statement Analysis

Dynavax Technologies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Dynavax Technologies shareholders. The income statement also shows Dynavax investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Dynavax Technologies Income Statement Chart

At this time, Dynavax Technologies' Selling General Administrative is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 64.2 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 3.7 M in 2024.

Other Operating Expenses Research Development Total Operating Expenses Total Revenue Selling And Marketing Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Dynavax Technologies. It is also known as Dynavax Technologies overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Total Revenue

Total revenue comprises all receipts Dynavax Technologies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Dynavax Technologies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Dynavax Technologies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.At this time, Dynavax Technologies' Selling General Administrative is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 64.2 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 3.7 M in 2024.

	2023	2024 (projected)
Interest Income	26.8M	28.1M
Non Recurring	15.4M	16.1M

Interest Income Non Recurring

Dynavax Technologies income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Minority Interest	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Interest Income	Net Interest Income	Selling And Marketing Expenses	Reconciled Depreciation
Depreciation And Amortization		0.76	0.5	0.06	0.05	0.06	0.09	0.54	0.03	0.07	0.3	0.27	0.08	0.04	-0.11	0.41	0.53	0.08	-0.06	0.8	0.23	-0.29	0.89	0.66
Interest Expense	0.76		0.35	0.09	0.09	-0.28	0.11	0.33	0.01	0.29	0.24	0.21	-0.02	0.03	-0.38	0.22	0.41	0.03	-0.2	0.75	0.08	-0.56	0.78	0.76
Other Operating Expenses	0.5	0.35		0.74	0.77	-0.06	0.79	0.81	0.77	-0.24	0.93	0.94	0.72	0.76	0.09	0.44	0.87	0.83	-0.14	0.76	0.55	0.22	0.69	0.19
Operating Income	0.06	0.09	0.74		0.98	-0.46	0.98	0.23	0.98	0.03	0.93	0.91	0.83	0.98	-0.09	-0.07	0.48	0.93	-0.27	0.3	0.12	0.04	0.24	-0.2
Ebit	0.05	0.09	0.77	0.98		-0.46	1.0	0.32	0.99	0.06	0.94	0.94	0.79	1.0	0.07	-0.03	0.57	0.97	-0.12	0.35	0.26	0.16	0.28	-0.2
Research Development	0.06	-0.28	-0.06	-0.46	-0.46		-0.46	0.24	-0.41	-0.73	-0.28	-0.28	0.0	-0.43	0.14	0.55	-0.18	-0.37	0.2	-0.15	-0.03	0.15	-0.16	0.06
Ebitda	0.09	0.11	0.79	0.98	1.0	-0.46		0.35	0.99	0.06	0.95	0.95	0.79	1.0	0.07	-0.01	0.59	0.97	-0.12	0.38	0.27	0.15	0.31	-0.18
Total Operating Expenses	0.54	0.33	0.81	0.23	0.32	0.24	0.35		0.32	-0.34	0.56	0.61	0.3	0.31	0.38	0.68	0.9	0.48	0.13	0.81	0.83	0.47	0.72	0.31
Net Income	0.03	0.01	0.77	0.98	0.99	-0.41	0.99	0.32		0.0	0.94	0.94	0.81	1.0	0.1	-0.01	0.55	0.98	-0.11	0.3	0.26	0.21	0.24	-0.26
Income Tax Expense	0.07	0.29	-0.24	0.03	0.06	-0.73	0.06	-0.34	0.0		-0.11	-0.11	-0.32	0.04	0.05	-0.64	-0.02	-0.03	0.14	0.09	-0.06	-0.25	0.12	0.0
Total Revenue	0.3	0.24	0.93	0.93	0.94	-0.28	0.95	0.56	0.94	-0.11		0.99	0.83	0.93	0.0	0.2	0.73	0.94	-0.22	0.57	0.37	0.14	0.51	0.0
Gross Profit	0.27	0.21	0.94	0.91	0.94	-0.28	0.95	0.61	0.94	-0.11	0.99		0.8	0.93	0.09	0.23	0.77	0.96	-0.16	0.58	0.45	0.23	0.5	-0.03
Cost Of Revenue	0.08	-0.02	0.72	0.83	0.79	0.0	0.79	0.3	0.81	-0.32	0.83	0.8		0.8	-0.14	0.15	0.37	0.75	-0.3	0.19	0.01	0.01	0.15	-0.21
Income Before Tax	0.04	0.03	0.76	0.98	1.0	-0.43	1.0	0.31	1.0	0.04	0.93	0.93	0.8		0.1	-0.02	0.56	0.98	-0.11	0.31	0.25	0.19	0.25	-0.26
Total Other Income Expense Net	-0.11	-0.38	0.09	-0.09	0.07	0.14	0.07	0.38	0.1	0.05	0.0	0.09	-0.14	0.1		0.14	0.35	0.23	0.83	0.04	0.68	0.81	0.0	-0.29
Minority Interest	0.41	0.22	0.44	-0.07	-0.03	0.55	-0.01	0.68	-0.01	-0.64	0.2	0.23	0.15	-0.02	0.14		0.45	0.11	0.03	0.39	0.37	0.18	0.33	0.16
Selling General Administrative	0.53	0.41	0.87	0.48	0.57	-0.18	0.59	0.9	0.55	-0.02	0.73	0.77	0.37	0.56	0.35	0.45		0.7	0.04	0.87	0.83	0.42	0.78	0.21
Net Income From Continuing Ops	0.08	0.03	0.83	0.93	0.97	-0.37	0.97	0.48	0.98	-0.03	0.94	0.96	0.75	0.98	0.23	0.11	0.7		-0.05	0.41	0.45	0.36	0.33	-0.24
Non Operating Income Net Other	-0.06	-0.2	-0.14	-0.27	-0.12	0.2	-0.12	0.13	-0.11	0.14	-0.22	-0.16	-0.3	-0.11	0.83	0.03	0.04	-0.05		-0.06	0.35	0.42	-0.06	0.0
Non Recurring	0.8	0.75	0.76	0.3	0.35	-0.15	0.38	0.81	0.3	0.09	0.57	0.58	0.19	0.31	0.04	0.39	0.87	0.41	-0.06		0.62	0.03	0.97	0.61
Interest Income	0.23	0.08	0.55	0.12	0.26	-0.03	0.27	0.83	0.26	-0.06	0.37	0.45	0.01	0.25	0.68	0.37	0.83	0.45	0.35	0.62		0.77	0.53	0.11
Net Interest Income	-0.29	-0.56	0.22	0.04	0.16	0.15	0.15	0.47	0.21	-0.25	0.14	0.23	0.01	0.19	0.81	0.18	0.42	0.36	0.42	0.03	0.77		-0.06	-0.4
Selling And Marketing Expenses	0.89	0.78	0.69	0.24	0.28	-0.16	0.31	0.72	0.24	0.12	0.51	0.5	0.15	0.25	0.0	0.33	0.78	0.33	-0.06	0.97	0.53	-0.06		0.69
Reconciled Depreciation	0.66	0.76	0.19	-0.2	-0.2	0.06	-0.18	0.31	-0.26	0.0	0.0	-0.03	-0.21	-0.26	-0.29	0.16	0.21	-0.24	0.0	0.61	0.11	-0.4	0.69

Click cells to compare fundamentals

Dynavax Technologies Account Relationship Matchups

Dynavax Technologies income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	6.7M	9.3M	7.0M	6.7M	7.3M	3.7M
Interest Expense	17.0M	19.1M	11.2M	6.7M	6.8M	4.0M
Other Operating Expenses	156.7M	121.8M	306.0M	440.2M	269.3M	282.8M
Operating Income	(121.5M)	(75.2M)	134.5M	283.5M	(37.0M)	(38.9M)
Ebit	(121.5M)	(56.2M)	88.7M	301.0M	2.4M	2.5M
Research Development	62.3M	28.6M	32.2M	46.6M	54.9M	51.9M
Ebitda	(114.8M)	(46.8M)	95.7M	307.7M	9.7M	10.1M
Total Operating Expenses	137.3M	107.9M	132.4M	178.0M	219.1M	230.1M
Net Income	(151.4M)	(91.8M)	76.7M	293.2M	(6.4M)	(6.7M)
Income Tax Expense	(1.2M)	16.5M	808K	1.1M	2.0M	2.1M
Total Revenue	35.2M	46.6M	439.4M	722.7M	232.3M	243.9M
Gross Profit	15.8M	32.6M	265.9M	460.5M	182.1M	191.2M
Cost Of Revenue	19.4M	13.9M	173.6M	262.2M	50.2M	52.1M
Income Before Tax	(152.6M)	(75.2M)	77.5M	294.3M	(4.4M)	(4.6M)
Total Other Income Expense Net	(31.1M)	(6.9M)	(57.0M)	10.8M	32.7M	34.3M
Selling General Administrative	48.7M	79.3M	100.2M	131.4M	152.9M	160.6M
Net Income From Continuing Ops	(155.2M)	(82.9M)	76.7M	293.2M	61.1M	64.2M
Non Operating Income Net Other	(3.4M)	4.5M	(53.5M)	9.8M	8.8M	9.3M
Net Income Applicable To Common Shares	(155.9M)	(75.2M)	81.3M	292.9M	336.8M	353.6M
Interest Income	3.4M	1.3M	140K	7.9M	26.8M	28.1M
Net Interest Income	(13.6M)	(17.8M)	(11.0M)	1.2M	20.0M	21.0M
Reconciled Depreciation	21.5M	9.3M	7.0M	6.7M	6.8M	8.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Dynavax Stock Analysis

When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dynavax Historical Income Statement

About Dynavax Income Statement Analysis

Dynavax Technologies Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Total Revenue

Dynavax Technologies income statement Correlations

Dynavax Technologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dynavax Technologies income statement Accounts

Also Currently Popular

Additional Tools for Dynavax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda
Income Before Tax	+ 1.0	Net Income
Net Income	+ 0.99	Ebit
Net Income	+ 0.99	Ebitda

Income Tax Expense	- 0.73	Research Development
Minority Interest	- 0.64	Income Tax Expense
Net Interest Income	- 0.56	Interest Expense
Ebitda	- 0.46	Research Development
Research Development	- 0.46	Ebit
Research Development	- 0.46	Operating Income